Contineum reports Q4 2025 net loss of $15.2M; upsizes ATM to $100M; Phase 2 IPF trial dosed

Contineum Therapeutics, Inc.

Net loss of $15.2M vs $14.6M in Q4 2024; R&D expenses $12.8M, G&A $4.4M.
Cash and equivalents $262.9M; cash runway projected through mid-2029.
Initiated dosing in PROPEL-IPF Phase 2 trial of PIPE-791 for IPF (324 patients).
Amended ATM sales agreement to offer up to $100M in common stock; lock-up until March 11, 2026.
Topline data from PIPE-791 Phase 1b chronic pain trial expected Q2 2026; J&J Phase 2 MDD trial recruiting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.